Frontier Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Frontier Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-488,015	Closed	-$30.2M	–	285
2022 Q3	$30.2M	Buy	488,015 +112,843	+30%	+$7.88M	0.35%	109
2022 Q2	$29.9M	Sell	375,172 -319,569	-46%	-$30.3M	0.34%	107
2022 Q1	$73.1M	Sell	694,741 -124,569	-15%	-$12.1M	0.66%	42
2021 Q4	$88.3M	Sell	819,310 -9,343	-1%	-$1.02M	0.7%	38
2021 Q3	$90.8M	Sell	828,653 -49,492	-6%	-$5.14M	0.71%	37
2021 Q2	$82.2M	Sell	878,145 -6,879	-0.8%	-$633K	0.6%	51
2021 Q1	$81.5M	Sell	885,024 -217,243	-20%	-$18.3M	0.62%	50
2020 Q4	$80.6M	Sell	1,102,267 -237,398	-18%	-$17.6M	0.6%	46
2020 Q3	$104M	Buy	1,339,665 +117,310	+10%	+$8.07M	0.91%	24
2020 Q2	$67.9M	Buy	+1,222,355	New	+$52.3M	0.6%	56

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frontier Capital Management's HZNP Position: Q4 2022 in Review

Frontier Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 488,015 shares — an estimated $30.2M sold.

Frontier Capital Management first reported a position in HZNP in Q2 2020 and held it in 10 quarters. The position peaked at $104M in Q3 2020. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Frontier Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Frontier Capital Management sold 488,015 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $30.2M.
Frontier Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 10 quarters.
Frontier Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $104M in Q3 2020.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Frontier Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.